2024 - Cancer Currents Blog
-
Drs. Ruth Pfeiffer and Peter Kraft of NCI’s Division of Cancer Epidemiology and Genetics discuss how breast cancer risk assessment tools are created and how people can use them to understand and manage their risk.
-
The immunotherapy drug durvalumab (Imfinzi) can help people with early-stage small cell lung cancer live longer, results from a large clinical trial show. Three years after starting treatment, nearly 60% of people who received the drug were still alive.
-
Recent results from several small clinical trials have suggested it may be possible to develop an effective immunotherapy for glioblastoma. Among them are findings from a four-patient trial testing a unique type of mRNA cancer vaccine.
-
A recent study showed that removing precancerous anal lesions can prevent anal cancer. Scientists are now studying how best to screen people at the high risk of anal cancer, including those with HIV, for these lesions.
-
When it comes to cancer drugs, researchers are moving away from a paradigm called the maximum tolerated dose. Instead, they’re focusing more on identifying doses that produce fewer side effects but are still effective against a person’s cancer.